Astellas Pays, And Pays Big, To Extend VelocImmune License With Regeneron
This article was originally published in The Pink Sheet Daily
The Japanese pharma is paying $165 million upfront for continued access to the fully human monoclonal antibody discovery platform through 2018.
You may also be interested in...
Astellas is on the verge of significantly increasing its heretofore small presence in oncology in the U.S. and abroad as it, along with its partners, prepares to file one and possibly two NDAs, including for the promising prostate cancer treatment MDV3100.
Community consent and other controversial practices involved with enrolling trauma patients in clinical trials will be addressed.
The billion-dollar expansion of Sanofi’s R&D relationship with antibody platform firm Regeneron Pharmaceuticals, announced in November, effectively turns Regeneron into Sanofi’s external antibody shop through 2017 and gives Paris-based Sanofi a potential bounty of monoclonal antibodies for its pipeline. just as its old-line small molecule products such as the blockbuster blood-thinner clopidogrel (Plavix) face generic competition for the first time.